Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Financing
Rome Therapeutics raises $72M in series B financing
Biotech company Rome Therapeutics has raised a further $72 million in financing to develop medicines for autoimmune diseases and continue its exploration of the “dark genome.”
September 20, 2023
Day Zero Diagnostics completes $16M financing round
Day Zero Diagnostics has completed a $16 million financing round, executed as a convertible note.
September 20, 2023
Broken String Biosciences raises $15M in series A financing round
Broken String Biosciences has closed a $15 million series A financing round.
September 19, 2023
Viome Life Sciences raises $86.5M in Series C financing round
This round brings Viome's total financing to $175 million, the firm said. A previous Series C financing round in October raised $67 million.
August 21, 2023
Veracyte raises full-year outlook on prostate cancer growth, reveals executive is leaving
In the second quarter, Veracyte reported sales of 15,000 Decipher Prostate tests. The 50% year-over-year increase in test volumes helped the company to report total sales of $90.3 million.
August 11, 2023
BARDA commits $30.5M to the development of musculoskeletal imaging system
BARDA has committed funding to support the development of a device that could quickly triage fracture severity in the wake of a chemical, biological, radiological, or nuclear attack and thereby preserve x-ray resources for the highest-priority patients.
August 11, 2023
CareDx reports 13% second-quarter revenue decrease from previous year
The company expects full-year 2023 revenues to be in the range of $240 million to $260 million.
August 9, 2023
Co-Diagnostics awarded over $2M from Bill & Melinda Gates Foundation for TB and HPV tests
Dwight Egan, CEO of Co-Diagnostics, said the grants would help support the worldwide effort to prevent the spread of both TB and HPV in countries where they have been endemic killers for generations.
July 26, 2023
Biotech firm AltPep closes $53M Series B financing round
AltPep said that the proceeds from the round will be used to accelerate its Sobin therapeutics for Alzheimer’s and Parkinson’s diseases into phase I clinical trials, as well as to advance its Soba diagnostic blood-based assay for Alzheimer’s disease.
June 23, 2023
Infectious disease NGS test developer Delve Bio closes $35M Series A financing
The company’s mNGS-based infectious disease testing platform uses technology developed at the University of California San Francisco Center for Next-Gen Precision Diagnostics.
June 20, 2023
Capitainer secures $5.7M to advance self-sampling technology
Capitainer will use the funding to increase production capacity, develop new products, and intensify sales and marketing efforts.
May 11, 2023
OpGen prices $3.5M public stock offering
Gross proceeds of the offering, before the deduction of the placement agent’s fees and other expenses, are expected to be $3.5 million, the firm said.
May 2, 2023
Page 1 of 6
Next Page
